Evolution of pediatric pharmaceutical forms for treatment of Hansen’s disease (leprosy)

References

• Pires CAA, Malcher CMSR, Abreu Júnior JMC, et al. Hanseníase em menores de 15 anos: a importância do exame de contato. Revista Paulista de Pediatria. 2012;30(2):292–295.
   Google Scholar
• Lastória JC, Abreu MAMM. Hanseníase: diagnóstico e tratamento. Diagn Tratamento. 2012;17(4):173–179.
   Google Scholar
• Ruiz-fuentes JL, Castillo RR, Llch G, et al. Leprosy in children: a Cuban experience on leprosy control. BMJ Paediatr Open. 2019;3(1):1–7.
   Google Scholar
• World Health Organization (WHO). Global leprosy update, 2019: moving towards a leprosy free world. Wkly Epidemiol Rec. 2019;94:389–412. accessed in October 11 2022
   Google Scholar
• Kar HK, Grupta R. Treatment of leprosy. Clinics in dermatology. 2015;33(1):55–65.
   PubMed Web of Science ®Google Scholar
• Pradhan S, Nayak BP, Dash G. Childhood leprosy: a review. Indian J Paediatr Dermatol. 2019;20:112–6.
   Google Scholar
• Rodrigues TSV, Gomes LC, Cortela DCB, et al. Factors associated with leprosy in children contacts of notified adults in an endemic region of Midwest Brazil. J Pediatr. 2019 96 5 593–599 .
   Google Scholar
• Eichelmann K, Salas-Alanis JC, Leprosy O-CJ. An Update: definition, Pathogenesis, Classification, Diagnosis, and Treatment. Actas Dermosifiliog. 2013;104(7):554–563.
   PubMedGoogle Scholar
• United States Pharmacopeial. Dapsone Compounded Oral Suspension. 2020.
   Google Scholar
• BRASIL. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Atenção Básica. Guia para o controle da hanseníase. Brasília: ministério da Saúde. Normas e Manuais Técnicos: Série A; 2002. p. 111.
   Google Scholar
• Oliveira MBBD, Diniz LMD. Leprosy among children under 15 years of age: literature review. An Bras Dermatol. 2016;91(2):196–203.
   PubMed Web of Science ®Google Scholar
• Liu F, Ranmal S, Batchelor HK, et al. Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: similarities and Differences in Paediatric and Geriatric Populations. Drugs. 2014;74:1871–1889.
   PubMed Web of Science ®Google Scholar
• Borges VRA, Simon A, Sena ARC, et al. Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int J Nanomedicine. 2013;8:535–44.
   PubMed Web of Science ®Google Scholar
• Brunaugh AD, Jan SU, Ferrati S, et al. Excipient-Free Pulmonary Delivery and Macrophage Targeting of Clofazimine via Air Jet Micronization. Mol Pharmaceutics. 2017;14(11):4019–4031.
   PubMed Web of Science ®Google Scholar
• Preis M. Orally Disintegrating Films and Mini-Tablets Innovative Dosage Forms of Choice for Pediatric Use. AAPS PharmasciTech. 2015;16(2):234–241.
   PubMed Web of Science ®Google Scholar
• Monteiro LD, Mota RMS, Martins-Melo FR, et al. Social determinants of leprosy in a hyperendemic State in North Brazil. Rev Saúde Pública. 2017;51:70.
   PubMed Web of Science ®Google Scholar
• Leano HAM, Kmfa A, Bueno IC, et al. Socioeconomic Factors Related to Leprosy: an Integrative Literature Review. Rev Bras Enferm. 2019;72(5):1405–1415.
   PubMed Web of Science ®Google Scholar
• Moreira M, Sarraguça M. How can oral pediatric formulations be improved? A challenge for the XXI century. Int J Pharm. 2022;590:e–119905.
   Google Scholar
• Trofimiuk M, Wasilewska K, Winnicka K. How to Modify Drug Release in Paediatric Dosage Forms? Novel Technologies and Modern Approaches With Regard to Children’s Population. Int J Mol Sci. 2019;20(13):3200.
   PubMed Web of Science ®Google Scholar
• Strickley RG. Pediatric Oral Formulations: an Updated Review of Commercially Available Pediatric Oral Formulations Since 2007. J pharm Sci. 2019;108(4):1335–1365.
   PubMed Web of Science ®Google Scholar
• Islan GA, Durán M, Cacicedo ML. Nanopharmaceuticals as a solution to neglected diseases: is it possible? Acta Tropical. 2017;170:16–42.
   PubMed Web of Science ®Google Scholar
• Chaves LL, Patriota Y, Soares-Sobrinho JL, et al. Drug Delivery Systems on Leprosy Therapy: moving Towards Eradication? Pharmaceutics. 2020;12(12):1202.
   PubMed Web of Science ®Google Scholar
• Eichelmann K, González SE, Salas-Alanis JC, et al. Leprosy. An Update: definition, Pathogenesis, Classification, Diagnosis, and Treatment. Actas Dermo-Sifiliográficas. 2013;104(7):554–563.
   PubMedGoogle Scholar
• Liu D, Zhang Q, Sun Y, et al. Drug resistance in Mycobacterium leprae from patients with leprosy in China. Clin Exp Dermatol. 2015;40(8):908–911.
   PubMed Web of Science ®Google Scholar
• Drug-resistant SP. M leprae. Clinical. Dermatolology. 2016;34(1):79–81.
   Google Scholar
• Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect. 2015;45(9):383–393.
   PubMed Web of Science ®Google Scholar
• Guragain S, Upadhayay N, Bhattarai BM. Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study. Clin Pharmacol. 2017;9:73–78.
   PubMed Web of Science ®Google Scholar
• Madhu M, Sreeram V, Nagendrakumar AVD, et al. A newer RP - HPLC method for the estimation of dapsone in bulk and in pharmaceutical formulations. Am J PharmTech Res. 2014;4(5):196–207.
   Google Scholar
• Zhu YI, Stiller MJ. Dapsone and Sulfones in dermatology: overview and update. J Am Acad Dermatol. 2011;45(3):420–434.
   Google Scholar
• Wolzel VEG. Innovative Use of Dapsone. Dermatol Clin. 2010;28(3):599–610.
   PubMed Web of Science ®Google Scholar
• Wolzel VEG, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103–124.
   PubMed Web of Science ®Google Scholar
• Ghaoui N, Hanna E, Abbas O, et al. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787–795.
   PubMed Web of Science ®Google Scholar
• Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67(2):290–298.
   PubMed Web of Science ®Google Scholar
• Baik J, Rosania GR. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. Plos One. 2012;7(10):e47494.
   PubMed Web of Science ®Google Scholar
• Li S, Chan JYW, Yan L, et al. Complexation of clofazimine by macrocyclic cucurbituril reduced its cardiotoxicity without affecting the antimycobacterial efficacy. Org Biomol Chem. 2016;14(31):7563–7569.
   PubMed Web of Science ®Google Scholar
• Yoon GS, Sud S, Keswani RK, et al. Phagocytosed clofazimine biocrystals can modulate innate immune signaling by inhibiting TNF alpha and boosting IL-1RA secretion. Mol Pharm. 2015;12(7):2517–2527.
   PubMedGoogle Scholar
• Hç A, Mosquera-giraldo LI, Pereira JM, et al. Rifampin stability and solution concentration enhancement through amorphous solid dispersion in cellulose ?-Carboxyalkanoate matrices. J Pharm Sci. 2018;107(1):127–138.
   PubMed Web of Science ®Google Scholar
• George J. Metabolism and interactions of antileprosy drugs. Biochem Pharmacol. 2020;177:e113993.
   PubMed Web of Science ®Google Scholar
• Fischer M. Leprosy - An overview of clinical features, diagnosis, and treatment. J Dtsch Dermatol Ges. 2017;15(8):801–827.
   Web of Science ®Google Scholar
• Maymone MBC, Venkatesh S, Laughter M, et al. Leprosy: treatment and management of complications. J Am Acad Dermatol. 2020;83:17–30
   PubMed Web of Science ®Google Scholar
• Bartos G, Sheuring R, Combs A, et al. Treatment of histoid leprosy: a lack of consensus. Int J Dermatology. 2020;59:1264–1269.
   PubMed Web of Science ®Google Scholar
• Ebenezer GJ, Scollard DM, et al. Treatment and evaluation advances in leprosy neuropathy. Neurotherapeutics. 2021;18(2337–50).
   PubMedGoogle Scholar
• Legendre DP, Muzny CA, Edwin S. Hansen’s disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32(1):27–37.
   PubMed Web of Science ®Google Scholar
• Khanna D, Wildt G, Duarte-Filho LA, et al. Improving treatment outcomes for leprosy in Pernambuco, Brazil: a qualitative study exploring the experiences and perceptions of retreatment patients and their carers. BMC Infect Dis. 2021;21:282.
   PubMed Web of Science ®Google Scholar
• Khan J, Rades T, Boyd B. The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations. Pharm Res. 2016;33(3):548–562.
   PubMed Web of Science ®Google Scholar
• Marques MS, Lima LA, Poletto F, et al. Nanotechnology for the treatment of pediatric diseases: a review. J Drug Deliv Sci Tech. 2022;75(1):e–103628.
   Google Scholar
• Veken MV, Brouwers J, Budts V, et al. Practical and operational considerations related to paediatric oral drug formulation: an industry survey. Int J Pharm. 2022;25(618):e121670.
   Google Scholar
• Belachew WA, Naafs B. Position statement: LEPROSY: diagnosis, Treatment and Follow-up. J Eur Acad Dermatol Venereol. 2019;33(7):1205–1213.
   PubMed Web of Science ®Google Scholar
• Mfoafo KA, Omidian M, Bertol CD, et al. Neonatal and pediatric oral drug delivery: hopes and hurdles. Int J Pharm. 2021;15(597):120296.
   Google Scholar
• Orubu ESF, Tuleu C. Medicines for children: flexible solid oral formulations. Bull World Health Organ. 2017;95(3):238–240.
   PubMed Web of Science ®Google Scholar
• Johannesson J, Hansson P, CAS B, et al. Manipulations and age-appropriateness of oral medications in pediatric oncology patients in Sweden: need for personalized dosage forms. Biomed Pharmacother. 2022;146:e112576.
   PubMed Web of Science ®Google Scholar
• Monteiro LM, Lione VF, Carmo FA, et al. Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomedicine. 2012;7(5):175–182.
   Google Scholar
• Wollmer E, Ungell AL, Nicolas JM, et al. Review of paediatric gastrointestinal physiology relevant to the absorption of orally administered medicines. Adv Drug Deliv Rev. 2022;181:e114084.
   PubMed Web of Science ®Google Scholar
• Ribeiro ACG, Taízia DS, Edilene R, et al. Book: medicamentos inalatórios orais: revisão sobre aspectos da formulação e dos dispositivos para liberação de dose. Atena Editora- Biomedicina e Farmácia. 2019;3(12):111–122.
   Google Scholar
• Stjepanovic AN, Todorovic NB, Tesic TZ, et al. Pharmaceutical excipients with potential to cause adverse effects in paediatric nasal medicines. Regul Toxicol Pharmacol. 2022;133:e105225.
   PubMed Web of Science ®Google Scholar
• Kurmi BD, Teckchandani P, Paliwal R, et al. Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Curr Drug Metab. 2017;18(5):481–495.
   PubMed Web of Science ®Google Scholar
• Hu Q, Sun W, Wang C, et al. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Ver. 2016;98:19–34.
   PubMed Web of Science ®Google Scholar
• Rocha D, Melo FCL, Ribeiro J. Uma adaptação da metodologia TRL. Rev Gest Engenh. 2017;4(1):45–56.
   Google Scholar
• Oliveira JHP, Arruda IES, Jir A, et al. Why do few drug delivery systems to combat neglected tropical diseases reach the market? An analysis from the technology’s stages. Expert Opin Ther Pat. 2022;32(1):89–114.
   PubMed Web of Science ®Google Scholar
• RUBIN BRUCEK, KANOH SOICHIRO, TANABE TSUYOSHI. inventors. Aerosolized dapsone as therapy for inflammation of the airway and abdominal mucociliary transport. AU: 2011227613B2; 2011.
   Google Scholar
• CLAUDIA REGINA ELIAS MANSUR, EDUARDO RICCI JUNIOR, VANIA EMERICH BUCO DE CAMPOS, JULIANA PERDIZ SENNA. inventors. Oil-in-water nanoemultion and process for producing same. IN: WO2014/117236A1; 2014.
   Google Scholar
• RUBIN BRUCEK, KANOH SOICHIRO, TANABE TSUYOSHI. inventors. Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport. US: US 2015/0040894A1; 2015.
   Google Scholar
• Altagracia Martínez MARINA, Ríos Castañeda LUISCAMILO, Kravzov Jinich JAIME. MARIA DE LOS ÁNGELES ARACELI DÁIZ RUÍZ, inventors. Soluble pharmaceutical forms of n,n’-diaminodiphenyl sulphone for optimum use in the treatment of various diseases. EP: WO 2010/126349; 2015.
   Google Scholar
• Yuhao HE. inventor. Pharmaceutical composition of clofazimine and medical application of composition. CN105693668A4: CN; 2016.
   Google Scholar
• LI ZHILI, BONI LAWRENCET, MILLER BRIANS, et al. inventors. High delivery rates for lipid-based drug formulations, and methods of treatment thereof. US: US 2017 014342 A1, 2017.
   Google Scholar
• WARNER KEVINS, PARASHAR AJAYP, SWAMINATHAN VIJAYA, et al. inventors. Topical dapsone and dapsone/Adapalene compositions and methods for use thereof. AU2018214139Al: AU; 2018.
   Google Scholar
• Thomas Hofmann STEFANUFER. inventors. Inhalable clofazimine formulation. WO2019/110099A1. 2019.
   Google Scholar
• Ashlee Brunaugh HUGHSMYTH. inventors. Inhalable composition of clofazimine and methods of use. WO2019/070693A1; 2019.
   Google Scholar
• Guerra HERCULES, Orlando DEANDRADE, Henrique Dos DAVID, et al. inventors. Processo de obtenção de micropartículas contendo rifampicina encapsulada em nanopartículas lipídicas. BR102017015666A2; 2019.
   Google Scholar
• TANG Qiusha HUCHUNMEI, Zhang Xia HUANGLILI. inventors. A kind of compound excretion body and preparation method thereof being loaded with rifampin. CN109364259A3; 2019.
   Google Scholar
• BONI LAWRENCET, MILLER BRIANS, Malinin VLADIMIR, et al. inventors. Sustained Release of Antiinfectives. US9827317B2: US; 2022.
   Google Scholar
• Mirnejad R, Asadi A, Khoshnood S, et al. Clofazimine: a useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother. 2018;105(1353–1359).
   PubMedGoogle Scholar
• Debotton N, Dahan A. Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms. Med Res Rev. 2017;37(1):52–97.
   PubMed Web of Science ®Google Scholar
• Dey P, Maiti S. Orodispersible tablets: a new trend in drug delivery. J Nat Sci Biol Med. 2010;1(1):2–5.
   PubMedGoogle Scholar
• Cilurzo F, Musazzi UM, Franzé S, et al. Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements. Drug Discov Today. 2018;23(2):251–259.
   PubMed Web of Science ®Google Scholar
• Dennison T, Smith J, Badhan R, et al. Formulation and bioequivalence testing of fixed-dose combination orally disintegrating tablets for the treatment of tuberculosis in paediatric population. J Pharm Sci. 2020;109(10):3105–3113.
   PubMed Web of Science ®Google Scholar
• Wang Liuyi LIUHAIYAN, Jincan WANG. inventors. Rifampicin composition freeze-dried orally disintegrating tablet and preparation method thereof. CN: CN102784126A. 2012.
   Google Scholar
• Manish Gupta KUMAR, Shripad Marathe WASUDEO, Shereedevi Nair VELAYDHAN. inventors. Dispersible composition. WO2016120258A1; 2016.
   Google Scholar
• Harris D, Hermans E, Klein S, et al. Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets: summary of September 2019 eupfi workshop. Eur J Pharm Biopharm. 2020;153:222–225.
   PubMed Web of Science ®Google Scholar
• Ingardrageet KURT, JOHANNE INGVILD, Johan Engelsen STEINAR, et al. inventors. Gelled oral pharmaceutical compositions. IN: WO2011/128628A2, 2011.
   Google Scholar
• Altagracia Martínez MARINA. inventor. Soluble pharmaceutical forms of n,n’-diaminodiphenyl sulphone for optimum use in the treatment of various diseases. IN: EP2425829A1, 2015.
   Google Scholar
• Chaves LL, Vieira ACC, Ferreira D, et al. Rational and precise development of amorphous polymeric systems with dapsone by response surface methodology. Inter J Biol Macromol. 2015;81:662–671.
   PubMed Web of Science ®Google Scholar
• Dongfei LIU, Zifan ZHANG, Guobing FENG. inventors. Group of drugs with improved dissolution properties and apparent solubility compound and preparation method thereof. CN113577029A1: CN; 2021.
   Google Scholar
• Malamatari M, Somavarapu S, Taylor KMG, et al. Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders. Expert Opin Drug Deliv. 2016;13(3):435–450.
   PubMed Web of Science ®Google Scholar
• Cavanagh THOMAS, Barman SHIKHAP, HAO TIAN, et al. inventors. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof. US: US2019/0169224A1; 2019.
   Google Scholar
• Malakhov MICHAELP, FANG FANG. inventors. Technology for the preparation of microparticles, US: US2018/028449A1, 2018.
   Google Scholar
• Regina Elias CLAUDIA, MANSUR EDUARDORICCI, JÚNIOR JULIANAPERDIZ, et al. inventors. Nanoemulsão óleo em água e seu processo de produção. IN BR102013002259
   Google Scholar
• Rodriguez Jesus FERNANDEZ. inventor. Branched receptor binding multi-subunit protein complexes for use in bacterial delivery vehicles, IN: US-11208437-B2, 2021.
   Google Scholar
• Kruijf W, Ehrhardt C. Inhalation delivery of complex drugs — the next steps. Curr Opin Pharmacol. 2017;36(52):52–57.
   PubMedGoogle Scholar
• Ehrhardt EC. Inhalation biopharmaceutics: progress towards comprehending the fate of inhaled medicines. Pharm Res. 2017;34(12):2451–2453.
   PubMed Web of Science ®Google Scholar
• Forest V, Pourchez J. Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 2022;183:114173.
   PubMed Web of Science ®Google Scholar
• Tomiyama TAKAMI, Umeda TOMOHIRO. inventors. Pharmaceutical composition for nasal administration. US: US2020/129426A1; 2020.
   Google Scholar
• Usach I, Martinez R, Festini T, et al. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986–2996.
   PubMed Web of Science ®Google Scholar
• Wang W. Tolerability of hypertonic injectables. Int J Pharm. 2015;490(1–2):308–315.
   PubMed Web of Science ®Google Scholar
• Babulal Jain MOHAB. inventor. Composition of stable lyophilized intravenous administration. 2014/MUM2008: 24/2011; 2011.
   Google Scholar
• Peng Xiao QINXUFENG, Kaiying REI. inventors. A type of freeze-dried preparation of rifampicin and its method of preparation. CN: CN104027314A1; 2014.
   Google Scholar
• Wenjing Zhang SHI, Huajuan JIAWANG. inventors. Rifampicin freeze-dried powder for injection and production method thereof. IN: CN113908129A1, 2021.
   Google Scholar
• REED STEVENG, Malcolm S. DUTHIE, inventors. Vaccine comprising Mycobacterium lepra polypeptides for the prevention, treatment, and diagnosis of leprosy. IN: WO 2018/053294 A1; 2018.
   Google Scholar
• IRVINE DARRELLJ, Stephan MATTHIAS, Moon JAEHYUN, et al. inventors. Methods and compositions for localized agent delivery. US: US 2018/0110733 A1, 2018.
   Google Scholar
• IRVINE DARRELLJ, Zheng YIRAN, TANG LI. inventors. Cell surface coupling of nanoparticles. AU2016/305087B2: WO/2017/027843; 2022.
   Google Scholar
• Pandey PC, Shukla S, Skoog SA, et al. Current advancements in transdermal biosensing and targeted drug delivery. Sensors (Basel) 2019 . 19(5):e10282019.
   Web of Science ®Google Scholar
• Hao Y, Li W, Zhou X, et al. Microneedles-based transdermal drug delivery systems: a review. J Biomed Nanotechnol. 2017;13(12):1581–1597.
   PubMed Web of Science ®Google Scholar
• Toscanini MA, Limeres MJ, Garrido AV, et al. Polymeric micelles and nanomedicines: shaping the future of next generation therapeutic strategies for infectious diseases. J Drug Deliv Sci Technol. 2021;66:e102927.
   Web of Science ®Google Scholar
• WARNER KEVINS, PARASHAR AJAYP, SWAMINATHAN VIJARA, et al. inventors. Topical dapsone and dapsone/adapalene compositions and methods for use thereof. IN: WO 2014/081674 A1; 2014.
   Google Scholar
• Lathrop ROBERTW, Daid W. OSBORNE, inventors. Emulsive Composition Containing Dapsone. US: US20130018104A1; 2013.
   Google Scholar
• John S, Garret. inventor. Topical treatment with dapsone in. G6pd-Deficient Patients IN. : US20130165526A1: 2013.
   Google Scholar
• Xinghao YANG. inventor. A kind of dapsone compound suspension and preparation method thereof and application. CN: CN113577022A1, 2021
   Google Scholar
• Sarid RONIT, Gedanken AHARON, BARAM-PINTO DANA. inventors. Pharmaceutical Compositions Comprising Water-Soluble Sulfonate-Protected Nanoparticles and Uses Thereof. US20120027809A1; 2012.
   Google Scholar
• Mikhail Gennadievich KOTELNIKOV, Fedor KHOROSHILOV, Vladimirovich KUMARAMRENDRA. inventors. Ointment for the treatment of skin infections. (RU: RU2637092C1). 2017
   Google Scholar
• Ying Ding YANGYANYE, Qihai YANNANGONG. inventors. Gel de rifampicina e método de preparação do mesmo. IN: CN107693484B1, 2021.
   Google Scholar
• Levis WILLIAMR, Frank T. MARTINIUK, inventors. Heat shockproteins from mycobacterium leprae and uses thereof. US: US8835619B2; 2014.
   Google Scholar
• Cutcliffe CULLEEN, James Bullard JHONEID, Schicklberger MARCUS, et al. inventors. Methods and composition relating to microbial treatment and diagnosis of skin disorders. CA2976956A1: US; 2016.
   Google Scholar
• YU CHONGXI, Yuhua Chen LINAXU, YAN BINBING, et al. inventors. High penetration compositions or prodrugs of antimicrobials and antimicrobial-related compounds. IN: RU2586287C2.
   Google Scholar